H A Pollack1. 1. Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor 48109-2029, USA. haroldp@sph.umich.edu
Abstract
OBJECTIVES: Hepatitis C (HCV) has emerged as a major epidemic among injection drug users (IDUs), with observed prevalence exceeding 70% in many American and European cities. This article explores the potential of syringe exchange programs (SEPs) to reduce HCV incidence and prevalence. DESIGN: A random-mixing epidemiological model is used to examine the potential impact of harm reduction interventions. METHODS: Steady-state analysis is used to scrutinize the impact of SEP on HCV incidence and prevalence and to examine the accuracy of short-term incidence analysis in predicting long-run program effects. RESULTS: SEP is predicted to have little impact on HCV incidence and prevalence within realistic populations of IDUs. CONCLUSIONS: Short-term incidence analysis substantially overstates SEP effectiveness and cost-effectiveness in preventing HCV. More comprehensive harm reduction models, coupled with referral of active IDUs to treatment, must complement syringe exchange to successfully contain highly infectious blood-borne diseases.
OBJECTIVES: Hepatitis C (HCV) has emerged as a major epidemic among injection drug users (IDUs), with observed prevalence exceeding 70% in many American and European cities. This article explores the potential of syringe exchange programs (SEPs) to reduce HCV incidence and prevalence. DESIGN: A random-mixing epidemiological model is used to examine the potential impact of harm reduction interventions. METHODS: Steady-state analysis is used to scrutinize the impact of SEP on HCV incidence and prevalence and to examine the accuracy of short-term incidence analysis in predicting long-run program effects. RESULTS: SEP is predicted to have little impact on HCV incidence and prevalence within realistic populations of IDUs. CONCLUSIONS: Short-term incidence analysis substantially overstates SEP effectiveness and cost-effectiveness in preventing HCV. More comprehensive harm reduction models, coupled with referral of active IDUs to treatment, must complement syringe exchange to successfully contain highly infectious blood-borne diseases.
Authors: Judith A Hahn; Dennis Wylie; Jesse Dill; Maria S Sanchez; James O Lloyd-Smith; Kimberly Page-Shafer; Wayne M Getz Journal: Epidemics Date: 2009-03 Impact factor: 4.396
Authors: Ava John-Baptiste; Man Wah Yeung; Victoria Leung; Gabrielle van der Velde; Murray Krahn Journal: Pharmacoeconomics Date: 2012-11-01 Impact factor: 4.981
Authors: Mary H Latka; Holly Hagan; Farzana Kapadia; Elizabeth T Golub; Sebastian Bonner; Jennifer V Campbell; Micaela H Coady; Richard S Garfein; Minya Pu; Dave L Thomas; Thelma K Thiel; Steffanie A Strathdee Journal: Am J Public Health Date: 2008-04-01 Impact factor: 9.308
Authors: Meghan Bellerose; Lin Zhu; Liesl M Hagan; William W Thompson; Liisa M Randall; Yelena Malyuta; Joshua A Salomon; Benjamin P Linas Journal: Int J Drug Policy Date: 2019-11-15